140 related articles for article (PubMed ID: 22955258)
1. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
Kang BW; Jeong JY; Chae YS; Lee SJ; Lee YJ; Choi JY; Lee IK; Jeon SW; Bae HI; Lee DK; Kwon OK; Chung HY; Yu W; Kim JG
Cancer Chemother Pharmacol; 2012 Nov; 70(5):735-41. PubMed ID: 22955258
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
Kang BW; Kim JG; Chae YS; Lee YJ; Lee SJ; Moon JH; Sohn SK; Jung MK; Jeon SW; Jang YJ; Seo J; Lee YH; Kwon O; Chung HY; Yu W
Invest New Drugs; 2012 Aug; 30(4):1671-5. PubMed ID: 21845514
[TBL] [Abstract][Full Text] [Related]
4. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
5. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
[TBL] [Abstract][Full Text] [Related]
7. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
9. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Kim SG; Hwang SH
World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.
Hosoda K; Azuma M; Katada C; Moriya H; Mieno H; Ishido K; Ema A; Ushiku H; Wada T; Washio M; Watanabe A; Higuchi K; Tanabe S; Koizumi W; Watanabe M; Yamashita K
Gastric Cancer; 2019 May; 22(3):598-606. PubMed ID: 30284080
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Fukuchi M; Ishiguro T; Ogata K; Suzuki O; Kumagai Y; Ishibashi K; Ishida H; Kuwano H; Mochiki E
Ann Surg Oncol; 2015 Oct; 22(11):3618-24. PubMed ID: 25663597
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Yamaguchi T; Takashima A; Nagashima K; Makuuchi R; Aizawa M; Ohashi M; Tashiro K; Yamada T; Kinoshita T; Hata H; Kawachi Y; Kawabata R; Tsuji T; Hihara J; Sakamoto T; Fukagawa T; Katai H; Higuchi K; Boku N
Ann Surg Oncol; 2020 Jan; 27(1):284-292. PubMed ID: 31535301
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
[No Abstract] [Full Text] [Related]
16. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Kim JS; Kim MA; Kim TM; Lee SH; Kim DW; Im SA; Kim TY; Kim WH; Yang HK; Heo DS; Bang YJ; Lee KU; Choe KJ; Kim NK
Br J Cancer; 2009 Mar; 100(5):732-8. PubMed ID: 19259093
[TBL] [Abstract][Full Text] [Related]
17. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes.
Oyama K; Fushida S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Tani T; Fujimura T; Ohta T
J Surg Oncol; 2012 May; 105(6):535-41. PubMed ID: 22006649
[TBL] [Abstract][Full Text] [Related]
19. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106).
Kurimoto K; Ishigure K; Mochizuki Y; Ishiyama A; Matsui T; Ito S; Nakayama H; Tanaka N; Kobayashi D; Sakamoto J; Nakao A; Kodera Y
Gastric Cancer; 2015 Apr; 18(2):354-9. PubMed ID: 24838732
[TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]